nct_id,source,last_update_submitted_date,registration_date,summary_results_date,study_type,phase,enrollment,recruitment_status,title,start_date,completion_date,primary_completion_date,has_summary_results,allocation,masking,main_sponsor,is_multicentric,registration_year,start_year,completion_year,is_prospective,registry_download_date,results_due_date,results_due,days_pcd_to_summary,is_summary_results_1y_pcd,summary_results_reporting
NCT00493298,CRU trials_12Sep2023.xlsx,2023-01-23,2007-06-27,NA,Observational,NA,6620,"Active, not recruiting",Tysabri Observational Program,2007-06-29T00:00:00Z,2029-01-03T00:00:00Z,2029-01-03T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2007,2007,2029,TRUE,2023-11-11,2030-01-03,FALSE,NA,NA,results_not_due
NCT00887146,CRU trials_12Sep2023.xlsx,2023-10-30,2009-04-22,NA,Interventional,Phase 3,360,Recruiting,Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma,2009-09-01T00:00:00Z,2025-10-01T00:00:00Z,2025-10-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE,2009,2009,2025,TRUE,2023-11-11,2026-10-01,FALSE,NA,NA,results_not_due
NCT01139892,CRU trials_12Sep2023.xlsx,2023-07-04,2010-06-02,NA,Observational,NA,291,Completed,The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES),2010-09-26T00:00:00Z,2022-10-01T00:00:00Z,2022-10-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2010,2010,2022,TRUE,2023-11-11,2023-10-01,TRUE,NA,NA,results_due_missing
NCT01194570,CRU trials_12Sep2023.xlsx,2023-05-19,2010-08-28,2017-03-30,Interventional,Phase 3,735,Completed,A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis,2011-03-02T00:00:00Z,2022-12-31T00:00:00Z,2015-07-23T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE,2010,2011,2022,TRUE,2023-11-11,2016-07-22,TRUE,616,FALSE,results_due_late
NCT01349582,CRU trials_12Sep2023.xlsx,2023-07-04,2011-05-04,NA,Interventional,Not Applicable,323,Completed,Flow Diversion in Intracranial Aneurysm Treatment,2011-05-02T00:00:00Z,2023-01-01T00:00:00Z,2023-01-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE,2011,2011,2023,TRUE,2023-11-11,2024-01-01,FALSE,NA,NA,results_not_due
NCT01412333,CRU trials_12Sep2023.xlsx,2023-03-02,2011-08-08,2017-03-30,Interventional,Phase 3,835,Completed,A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis,2011-09-20T00:00:00Z,2022-12-30T00:00:00Z,2015-05-12T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE,2011,2011,2022,TRUE,2023-11-11,2016-05-11,TRUE,688,FALSE,results_due_late
NCT01442194,CRU trials_12Sep2023.xlsx,2021-12-28,2011-08-21,NA,Observational,NA,3076,Completed,Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies,2011-08-01T00:00:00Z,2020-07-10T00:00:00Z,2020-07-10T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2011,2011,2020,TRUE,2023-11-11,2021-07-10,TRUE,NA,NA,results_due_missing
NCT01665144,CRU trials_12Sep2023.xlsx,2023-10-13,2012-08-03,2018-08-06,Interventional,Phase 3,1651,Completed,Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND),2012-12-20T00:00:00Z,2023-03-30T00:00:00Z,2016-04-29T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE,2012,2012,2023,TRUE,2023-11-11,2017-04-29,TRUE,829,FALSE,results_due_late
NCT01960348,CRU trials_12Sep2023.xlsx,2018-11-18,2013-10-09,2018-08-07,Interventional,Phase 3,225,Completed,"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",2013-11-01T00:00:00Z,2017-08-01T00:00:00Z,2017-08-01T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE,2013,2013,2017,TRUE,2023-11-11,2018-08-01,TRUE,371,FALSE,results_due_late
NCT02098252,CRU trials_12Sep2023.xlsx,2023-07-04,2014-03-25,NA,Interventional,Not Applicable,1000,Recruiting,Treatment of Brain AVMs (TOBAS) Study,2014-05-01T00:00:00Z,2036-01-01T00:00:00Z,2035-01-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE,2014,2014,2036,TRUE,2023-11-11,2036-01-01,FALSE,NA,NA,results_not_due
NCT02255656,CRU trials_12Sep2023.xlsx,2022-03-21,2014-09-30,2021-06-30,Interventional,Phase 4,1062,Completed,Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409,2015-01-07T00:00:00Z,2020-07-15T00:00:00Z,2020-07-15T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE,2014,2015,2020,TRUE,2023-11-11,2021-07-15,TRUE,350,TRUE,results_timely
NCT02388165,CRU trials_12Sep2023.xlsx,2020-12-11,2015-03-09,2020-06-05,Interventional,Phase 2,3450,Terminated,Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation,2015-07-02T00:00:00Z,2019-06-27T00:00:00Z,2019-06-26T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE,2015,2015,2019,TRUE,2023-11-11,2020-06-25,TRUE,345,TRUE,results_timely
NCT02398656,CRU trials_12Sep2023.xlsx,2022-05-16,2015-03-20,NA,Interventional,Phase 3,1274,Recruiting,A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion,2015-04-01T00:00:00Z,2024-12-01T00:00:00Z,2024-12-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE,2015,2015,2024,TRUE,2023-11-11,2025-12-01,FALSE,NA,NA,results_not_due
NCT02414165,CRU trials_12Sep2023.xlsx,2020-02-06,2015-04-03,NA,Interventional,Phase 2/Phase 3,403,Terminated,The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma,2015-11-30T00:00:00Z,2019-12-20T00:00:00Z,2019-05-31T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE,2015,2015,2019,TRUE,2023-11-11,2020-05-30,TRUE,NA,NA,results_due_missing
NCT02485600,CRU trials_12Sep2023.xlsx,2021-06-23,2015-06-26,NA,Observational,NA,88,Completed,Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients,2015-10-19T00:00:00Z,2020-02-26T00:00:00Z,2020-02-26T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2015,2015,2020,TRUE,2023-11-11,2021-02-25,TRUE,NA,NA,results_due_missing
NCT02547818,CRU trials_12Sep2023.xlsx,2021-11-08,2015-09-10,NA,Interventional,Phase 3,620,Completed,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,2015-09-15T00:00:00Z,2020-11-18T00:00:00Z,2020-11-13T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2015,2015,2020,TRUE,2023-11-11,2021-11-13,TRUE,NA,NA,results_due_missing
NCT02623699,CRU trials_12Sep2023.xlsx,2023-07-07,2015-11-24,2023-05-17,Interventional,Phase 3,176,Completed,"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",2016-01-20T00:00:00Z,2021-07-16T00:00:00Z,2021-07-16T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2015,2016,2021,TRUE,2023-11-11,2022-07-16,TRUE,670,FALSE,results_due_late
NCT02638207,CRU trials_12Sep2023.xlsx,2021-01-28,2015-12-16,2020-09-03,Interventional,Phase 3,142,Completed,Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy,2017-09-27T00:00:00Z,2019-09-05T00:00:00Z,2019-09-05T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2015,2017,2019,TRUE,2023-11-11,2020-09-04,TRUE,364,TRUE,results_timely
NCT02655614,CRU trials_12Sep2023.xlsx,2020-08-04,2016-01-07,NA,Interventional,Phase 1,54,Completed,"A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",2016-05-31T00:00:00Z,2020-03-16T00:00:00Z,2020-03-16T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2016,2016,2020,TRUE,2023-11-11,2021-03-16,TRUE,NA,NA,results_due_missing
NCT02667587,CRU trials_12Sep2023.xlsx,2023-11-03,2016-01-26,2021-11-30,Interventional,Phase 3,716,"Active, not recruiting","An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",2016-05-09T00:00:00Z,2024-02-19T00:00:00Z,2020-12-22T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE,2016,2016,2024,TRUE,2023-11-11,2021-12-22,TRUE,343,TRUE,results_timely
NCT02685605,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx;registry-org-name-query,2023-05-09,2016-02-05,NA,Interventional,Phase 3,314,Recruiting,Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme,2016-12-09T00:00:00Z,2024-03-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE,2016,2016,2024,TRUE,2023-11-11,2024-11-30,FALSE,NA,NA,results_not_due
NCT02688985,CRU trials_12Sep2023.xlsx,2023-08-28,2016-02-18,NA,Interventional,Phase 3,132,Completed,Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS),2016-04-29T00:00:00Z,2023-04-11T00:00:00Z,2023-04-11T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE,2016,2016,2023,TRUE,2023-11-11,2024-04-10,FALSE,NA,NA,results_not_due
NCT02782741,CRU trials_12Sep2023.xlsx,2023-06-01,2016-05-23,2021-03-12,Interventional,Phase 3,100,Completed,Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease,2016-11-02T00:00:00Z,2023-05-31T00:00:00Z,2020-03-19T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2016,2016,2023,TRUE,2023-11-11,2021-03-19,TRUE,358,TRUE,results_timely
NCT02792218,CRU trials_12Sep2023.xlsx,2021-09-03,2016-06-02,2020-09-18,Interventional,Phase 3,930,Completed,Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis,2016-09-20T00:00:00Z,2020-07-20T00:00:00Z,2019-07-05T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2016,2016,2020,TRUE,2023-11-11,2020-07-04,TRUE,441,FALSE,results_due_late
NCT02796261,CRU trials_12Sep2023.xlsx,2022-01-19,2016-06-03,NA,Interventional,Phase 3,343,"Active, not recruiting",Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients,2016-07-01T00:00:00Z,2023-06-01T00:00:00Z,2023-06-01T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE,2016,2016,2023,TRUE,2023-11-11,2024-05-31,FALSE,NA,NA,results_not_due
NCT02906020,CRU trials_12Sep2023.xlsx,2022-05-03,2016-09-14,2021-12-16,Interventional,Phase 2,273,Terminated,"A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation",2016-12-15T00:00:00Z,2021-05-27T00:00:00Z,2020-12-18T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE,2016,2016,2021,TRUE,2023-11-11,2021-12-18,TRUE,363,TRUE,results_timely
NCT02927080,CRU trials_12Sep2023.xlsx,2022-09-14,2016-10-05,2020-09-18,Interventional,Phase 2,95,Terminated,Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD),2016-11-01T00:00:00Z,2019-10-09T00:00:00Z,2019-09-17T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2016,2016,2019,TRUE,2023-11-11,2020-09-16,TRUE,367,FALSE,results_due_late
NCT03044249,CRU trials_12Sep2023.xlsx,2021-03-05,2017-01-31,2021-01-29,Interventional,Phase 2,81,Terminated,A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression,2017-05-04T00:00:00Z,2020-01-30T00:00:00Z,2020-01-30T00:00:00Z,TRUE,Randomized,Triple,OTHER,TRUE,2017,2017,2020,TRUE,2023-11-11,2021-01-29,TRUE,365,TRUE,results_timely
NCT03068754,CRU trials_12Sep2023.xlsx,2020-09-18,2017-02-23,2020-08-14,Interventional,Phase 2/Phase 3,143,Terminated,Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS),2017-06-22T00:00:00Z,2019-11-25T00:00:00Z,2019-11-25T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE,2017,2017,2019,TRUE,2023-11-11,2020-11-24,TRUE,263,TRUE,results_timely
NCT03070119,CRU trials_12Sep2023.xlsx,2023-05-19,2017-02-28,NA,Interventional,Phase 3,138,"Active, not recruiting",Long-Term Evaluation of BIIB067 (Tofersen),2017-03-08T00:00:00Z,2024-06-13T00:00:00Z,2024-06-13T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE,2017,2017,2024,TRUE,2023-11-11,2025-06-13,FALSE,NA,NA,results_not_due
NCT03083665,CRU trials_12Sep2023.xlsx,2023-11-08,2017-02-28,2022-12-15,Interventional,Phase 3,449,Completed,A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy,2017-08-22T00:00:00Z,2022-06-30T00:00:00Z,2022-06-30T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2017,2017,2022,TRUE,2023-11-11,2023-06-30,TRUE,168,TRUE,results_timely
NCT03085810,CRU trials_12Sep2023.xlsx,2023-10-23,2017-03-16,NA,Interventional,Phase 3,1239,Completed,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),2017-03-24T00:00:00Z,2023-04-27T00:00:00Z,2023-04-27T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2017,2017,2023,TRUE,2023-11-11,2024-04-26,FALSE,NA,NA,results_not_due
NCT03090789,CRU trials_12Sep2023.xlsx,2023-09-26,2017-03-10,NA,Observational,NA,2000,Recruiting,FA Clinical Outcome Measures,2001-01-01T00:00:00Z,2030-01-01T00:00:00Z,2030-01-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2017,2001,2030,FALSE,2023-11-11,2031-01-01,FALSE,NA,NA,results_not_due
NCT03098511,CRU trials_12Sep2023.xlsx,2023-05-03,2017-03-22,NA,Interventional,Not Applicable,333,"Active, not recruiting",CT-Perfusion for Neurological Diagnostic Evaluation,2017-04-25T00:00:00Z,2023-08-31T00:00:00Z,2023-08-31T00:00:00Z,FALSE,NA,None (Open Label),OTHER,TRUE,2017,2017,2023,TRUE,2023-11-11,2024-08-30,FALSE,NA,NA,results_not_due
NCT03160898,CRU trials_12Sep2023.xlsx,2020-08-21,2017-05-12,2020-08-05,Interventional,Phase 2,458,Completed,"A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)",2017-07-24T00:00:00Z,2019-03-07T00:00:00Z,2019-03-07T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2017,2017,2019,TRUE,2023-11-11,2020-03-06,TRUE,517,FALSE,results_due_late
NCT03179501,CRU trials_12Sep2023.xlsx,2018-10-18,2017-06-05,NA,Interventional,Phase 1,4,Terminated,"NP001, Alzheimer's Disease, and Blood Markers of Inflammation",2017-09-01T00:00:00Z,2018-07-31T00:00:00Z,2018-07-31T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,FALSE,2017,2017,2018,TRUE,2023-11-11,2019-07-31,TRUE,NA,NA,results_due_missing
NCT03186989,CRU trials_12Sep2023.xlsx,2023-02-16,2017-06-06,NA,Interventional,Phase 1/Phase 2,46,Completed,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",2017-10-12T00:00:00Z,2022-05-13T00:00:00Z,2022-05-12T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2017,2017,2022,TRUE,2023-11-11,2023-05-12,TRUE,NA,NA,results_due_missing
NCT03192332,CRU trials_12Sep2023.xlsx,2023-03-06,2017-06-12,NA,Interventional,Not Applicable,410,Completed,Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke,2017-11-29T00:00:00Z,2021-08-11T00:00:00Z,2021-05-14T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE,2017,2017,2021,TRUE,2023-11-11,2022-05-14,TRUE,NA,NA,results_due_missing
NCT03260920,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-10-04,2017-07-19,NA,Interventional,Phase 2,112,"Active, not recruiting",Intranasal Oxytocin for Frontotemporal Dementia,2018-01-31T00:00:00Z,2024-12-31T00:00:00Z,2023-06-30T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,TRUE,2017,2018,2024,TRUE,2023-11-11,2024-06-29,FALSE,NA,NA,results_not_due
NCT03309579,CRU trials_12Sep2023.xlsx,2023-04-20,2017-10-10,NA,Interventional,Not Applicable,740,Recruiting,SAHaRA: A Randomized Controlled Trial,2018-02-12T00:00:00Z,2024-09-01T00:00:00Z,2023-09-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE,2017,2018,2024,TRUE,2023-11-11,2024-08-31,FALSE,NA,NA,results_not_due
NCT03315130,CRU trials_12Sep2023.xlsx,2022-07-26,2017-10-16,2022-05-31,Interventional,Phase 2,45,Completed,Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis,2017-10-11T00:00:00Z,2020-11-19T00:00:00Z,2018-12-10T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2017,2017,2020,TRUE,2023-11-11,2019-12-10,TRUE,1268,FALSE,results_due_late
NCT03318523,CRU trials_12Sep2023.xlsx,2022-02-15,2017-10-19,2021-10-25,Interventional,Phase 2,357,Terminated,"Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease",2018-01-10T00:00:00Z,2021-04-29T00:00:00Z,2020-10-26T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2017,2018,2021,TRUE,2023-11-11,2021-10-26,TRUE,364,TRUE,results_timely
NCT03362658,CRU trials_12Sep2023.xlsx,2023-01-24,2017-10-18,NA,Observational,NA,700,Recruiting,Novel MRI Biomarkers for Monitoring Disease Progression in ALS,2016-10-01T00:00:00Z,2023-12-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2017,2016,2023,FALSE,2023-11-11,2024-11-30,FALSE,NA,NA,results_not_due
NCT03364036,CRU trials_12Sep2023.xlsx,2023-02-20,2017-12-01,2021-05-04,Interventional,Phase 4,270,Completed,Evaluation of the Onset of Action in Highly Active MS (MAGNIFY),2018-05-28T00:00:00Z,2022-02-21T00:00:00Z,2020-05-05T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE,2017,2018,2022,TRUE,2023-11-11,2021-05-05,TRUE,364,TRUE,results_timely
NCT03402919,CRU trials_12Sep2023.xlsx,2019-10-02,2018-01-11,NA,Observational,NA,2300,Unknown status,Comprehensive Assessment of Neurodegeneration and Dementia,2016-06-01T00:00:00Z,2023-09-01T00:00:00Z,2023-09-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2018,2016,2023,FALSE,2023-11-11,2024-08-31,FALSE,NA,NA,results_not_due
NCT03478982,CRU trials_12Sep2023.xlsx,2021-02-02,2018-03-07,2020-12-16,Interventional,Phase 2,156,Completed,"Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern",2018-03-16T00:00:00Z,2020-01-04T00:00:00Z,2019-12-22T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2018,2018,2020,TRUE,2023-11-11,2020-12-21,TRUE,360,TRUE,results_timely
NCT03504917,CRU trials_12Sep2023.xlsx,2021-10-26,2018-04-12,2021-03-02,Interventional,Phase 3,322,Terminated,A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension,2018-08-08T00:00:00Z,2020-07-01T00:00:00Z,2020-03-04T00:00:00Z,TRUE,Randomized,Double,INDUSTRY,TRUE,2018,2018,2020,TRUE,2023-11-11,2021-03-04,TRUE,363,TRUE,results_timely
NCT03505021,CRU trials_12Sep2023.xlsx,2022-04-22,2018-04-16,2021-07-01,Interventional,Phase 3,496,Completed,Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS,2018-06-21T00:00:00Z,2020-07-23T00:00:00Z,2020-07-23T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2018,2018,2020,TRUE,2023-11-11,2021-07-23,TRUE,343,TRUE,results_timely
NCT03529045,CRU trials_12Sep2023.xlsx,2023-05-22,2018-02-22,NA,Observational,NA,2000,"Active, not recruiting",Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.,2018-02-05T00:00:00Z,2025-04-30T00:00:00Z,2024-10-30T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2018,2018,2025,TRUE,2023-11-11,2025-10-30,FALSE,NA,NA,results_not_due
NCT03599245,CRU trials_12Sep2023.xlsx,2023-10-25,2018-06-25,NA,Interventional,Phase 3,1500,"Active, not recruiting",This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS),2018-07-12T00:00:00Z,2025-03-11T00:00:00Z,2025-02-23T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2018,2018,2025,TRUE,2023-11-11,2026-02-23,FALSE,NA,NA,results_not_due
NCT03626012,CRU trials_12Sep2023.xlsx,2022-01-13,2018-08-07,NA,Interventional,Phase 1,106,Completed,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",2018-09-10T00:00:00Z,2021-11-17T00:00:00Z,2021-11-17T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2018,2018,2021,TRUE,2023-11-11,2022-11-17,TRUE,NA,NA,results_due_missing
NCT03650114,CRU trials_12Sep2023.xlsx,2023-09-29,2018-08-17,NA,Interventional,Phase 3,2060,Recruiting,"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS",2018-12-28T00:00:00Z,2028-09-07T00:00:00Z,2027-12-30T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2018,2018,2028,TRUE,2023-11-11,2028-12-29,FALSE,NA,NA,results_not_due
NCT03655236,CRU trials_12Sep2023.xlsx,2023-07-24,2018-08-18,NA,Interventional,Phase 2,504,Recruiting,PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706,2019-02-18T00:00:00Z,2024-03-01T00:00:00Z,2024-03-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2018,2019,2024,TRUE,2023-11-11,2025-03-01,FALSE,NA,NA,results_not_due
NCT03661528,CRU trials_12Sep2023.xlsx,2023-09-11,2018-08-30,NA,Interventional,Phase 4,530,Completed,Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor,2019-06-06T00:00:00Z,2023-08-09T00:00:00Z,2023-05-27T00:00:00Z,FALSE,Randomized,Single,INDUSTRY,TRUE,2018,2019,2023,TRUE,2023-11-11,2024-05-26,FALSE,NA,NA,results_not_due
NCT03689972,CRU trials_12Sep2023.xlsx,2023-08-17,2018-09-27,NA,Interventional,Phase 3,500,Completed,"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",2018-11-27T00:00:00Z,2023-07-24T00:00:00Z,2023-01-31T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE,2018,2018,2023,TRUE,2023-11-11,2024-01-31,FALSE,NA,NA,results_not_due
NCT03709784,CRU trials_12Sep2023.xlsx,2022-09-19,2018-10-15,NA,Observational,NA,48,"Active, not recruiting",Spinraza in Adult Spinal Muscular Atrophy,2018-08-16T00:00:00Z,2024-01-01T00:00:00Z,2024-01-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2018,2018,2024,FALSE,2023-11-11,2024-12-31,FALSE,NA,NA,results_not_due
NCT03737812,CRU trials_12Sep2023.xlsx,2021-12-15,2018-11-06,NA,Interventional,Phase 2,123,Completed,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis,2019-02-27T00:00:00Z,2021-08-30T00:00:00Z,2021-01-15T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2018,2019,2021,TRUE,2023-11-11,2022-01-15,TRUE,NA,NA,results_due_missing
NCT03737851,CRU trials_12Sep2023.xlsx,2021-12-01,2018-11-06,NA,Interventional,Phase 2,208,Completed,A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis,2018-12-11T00:00:00Z,2021-09-09T00:00:00Z,2021-01-07T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2018,2018,2021,TRUE,2023-11-11,2022-01-07,TRUE,NA,NA,results_due_missing
NCT03750552,CRU trials_12Sep2023.xlsx,2022-08-18,2018-11-20,2022-07-20,Interventional,Phase 3,195,Completed,Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure,2019-01-24T00:00:00Z,2021-07-21T00:00:00Z,2021-07-21T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2018,2019,2021,TRUE,2023-11-11,2022-07-21,TRUE,364,TRUE,results_timely
NCT03770403,CRU trials_12Sep2023.xlsx,2023-06-21,2018-11-16,2023-06-21,Interventional,Phase 3,151,Completed,A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.,2019-03-01T00:00:00Z,2022-06-30T00:00:00Z,2022-06-23T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE,2018,2019,2022,TRUE,2023-11-11,2023-06-23,TRUE,363,TRUE,results_timely
NCT03785678,CRU trials_12Sep2023.xlsx,2023-04-27,2018-12-19,NA,Interventional,Phase 3,452,Completed,Tenecteplase in Stroke Patients Between 4.5 and 24 Hours,2019-03-02T00:00:00Z,2023-02-28T00:00:00Z,2023-02-28T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2018,2019,2023,TRUE,2023-11-11,2024-02-28,FALSE,NA,NA,results_not_due
NCT03829657,CRU trials_12Sep2023.xlsx,2022-12-29,2019-01-10,2022-11-08,Interventional,Phase 3,203,Terminated,Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure,2019-02-22T00:00:00Z,2021-11-10T00:00:00Z,2021-11-10T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE,2019,2019,2021,TRUE,2023-11-11,2022-11-10,TRUE,363,TRUE,results_timely
NCT03836716,CRU trials_12Sep2023.xlsx,2023-08-22,2019-02-07,2023-05-15,Interventional,Phase 3,120,Terminated,Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial,2019-09-19T00:00:00Z,2021-07-02T00:00:00Z,2021-07-02T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE,2019,2019,2021,TRUE,2023-11-11,2022-07-02,TRUE,682,FALSE,results_due_late
NCT03855137,CRU trials_12Sep2023.xlsx,2023-01-18,2019-02-25,2023-01-18,Interventional,Phase 3,778,Completed,"Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine",2019-03-11T00:00:00Z,2022-01-20T00:00:00Z,2022-01-20T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE,2019,2019,2022,TRUE,2023-11-11,2023-01-20,TRUE,363,TRUE,results_timely
NCT03863080,CRU trials_12Sep2023.xlsx,2021-10-06,2019-02-20,NA,Interventional,Phase 2,17,Completed,A Study of RVT-1401 in Myasthenia Gravis (MG) Patients,2019-05-21T00:00:00Z,2020-12-21T00:00:00Z,2020-10-07T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2019,2019,2020,TRUE,2023-11-11,2021-10-07,TRUE,NA,NA,results_due_missing
NCT03866603,CRU trials_12Sep2023.xlsx,2023-09-06,2019-03-01,NA,Observational,NA,25000,Recruiting,Rostock International Parkinson's Disease Study (ROPAD),2019-05-30T00:00:00Z,2025-12-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2019,2019,2025,TRUE,2023-11-11,2026-12-31,FALSE,NA,NA,results_not_due
NCT03889249,CRU trials_12Sep2023.xlsx,2023-05-11,2019-03-20,NA,Interventional,Phase 3,1600,Completed,Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke,2019-12-10T00:00:00Z,2023-04-30T00:00:00Z,2022-04-26T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE,2019,2019,2023,TRUE,2023-11-11,2023-04-26,TRUE,NA,NA,results_due_missing
NCT03920293,CRU trials_12Sep2023.xlsx,2023-08-16,2019-04-16,2022-05-03,Interventional,Phase 3,175,Completed,Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis,2019-03-26T00:00:00Z,2023-05-25T00:00:00Z,2021-05-11T00:00:00Z,TRUE,Randomized,Triple,INDUSTRY,TRUE,2019,2019,2023,FALSE,2023-11-11,2022-05-11,TRUE,357,TRUE,results_timely
NCT03936361,CRU trials_12Sep2023.xlsx,2023-07-10,2019-05-01,NA,Interventional,Phase 3,1456,Recruiting,Statins In Intracerbral Hemorrhage,2020-06-10T00:00:00Z,2026-12-31T00:00:00Z,2026-06-30T00:00:00Z,FALSE,Randomized,Single,OTHER,FALSE,2019,2020,2026,TRUE,2023-11-11,2027-06-30,FALSE,NA,NA,results_not_due
NCT03943290,CRU trials_12Sep2023.xlsx,2022-09-13,2019-04-17,2021-03-11,Interventional,Phase 2,62,Terminated,Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX),2019-05-10T00:00:00Z,2020-03-11T00:00:00Z,2020-03-11T00:00:00Z,TRUE,Randomized,None (Open Label),INDUSTRY,TRUE,2019,2019,2020,TRUE,2023-11-11,2021-03-11,TRUE,365,TRUE,results_timely
NCT03950076,CRU trials_12Sep2023.xlsx,2023-01-23,2019-05-10,NA,Interventional,Phase 4,1200,Recruiting,EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF),2019-09-20T00:00:00Z,2024-04-01T00:00:00Z,2024-04-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE,2019,2019,2024,TRUE,2023-11-11,2025-04-01,FALSE,NA,NA,results_not_due
NCT03970447,CRU trials_12Sep2023.xlsx,2023-11-01,2019-05-23,NA,Interventional,Phase 2/Phase 3,1030,Recruiting,A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma,2019-07-30T00:00:00Z,2028-06-01T00:00:00Z,2026-06-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE,2019,2019,2028,TRUE,2023-11-11,2027-06-01,FALSE,NA,NA,results_not_due
NCT03971422,CRU trials_12Sep2023.xlsx,2023-08-22,2019-05-29,2023-07-27,Interventional,Phase 3,200,Completed,A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis,2019-06-03T00:00:00Z,2021-10-26T00:00:00Z,2021-08-31T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2019,2019,2021,TRUE,2023-11-11,2022-08-31,TRUE,695,FALSE,results_due_late
NCT03972306,CRU trials_12Sep2023.xlsx,2023-10-18,2019-05-29,NA,Interventional,Phase 1,134,"Active, not recruiting","A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",2019-08-12T00:00:00Z,2025-06-20T00:00:00Z,2023-01-27T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE,2019,2019,2025,TRUE,2023-11-11,2024-01-27,FALSE,NA,NA,results_not_due
NCT03976349,CRU trials_12Sep2023.xlsx,2023-04-11,2019-06-04,NA,Interventional,Phase 1,82,Recruiting,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease",2019-08-12T00:00:00Z,2023-12-02T00:00:00Z,2023-12-02T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2019,2019,2023,TRUE,2023-11-11,2024-12-01,FALSE,NA,NA,results_not_due
NCT04003974,CRU trials_12Sep2023.xlsx,2022-02-08,2019-06-25,NA,Interventional,Phase 2,80,Completed,Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD),2019-08-09T00:00:00Z,2021-01-28T00:00:00Z,2021-01-28T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2019,2019,2021,TRUE,2023-11-11,2022-01-28,TRUE,NA,NA,results_due_missing
NCT04057898,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-10-13,2019-08-06,NA,Interventional,Phase 2/Phase 3,230,Recruiting,Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS,2020-05-28T00:00:00Z,2024-12-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2019,2020,2024,TRUE,2023-11-11,2024-11-30,FALSE,NA,NA,results_not_due
NCT04095793,CRU trials_12Sep2023.xlsx,2022-11-07,2019-08-01,2022-11-07,Interventional,Phase 3,110,Terminated,Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure,2019-09-19T00:00:00Z,2021-11-12T00:00:00Z,2021-11-12T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE,2019,2019,2021,TRUE,2023-11-11,2022-11-12,TRUE,360,TRUE,results_timely
NCT04115293,CRU trials_12Sep2023.xlsx,2023-05-02,2019-10-02,2022-12-19,Interventional,Phase 3,174,Completed,"Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis",2019-09-17T00:00:00Z,2021-12-30T00:00:00Z,2021-12-30T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2019,2019,2021,FALSE,2023-11-11,2022-12-30,TRUE,354,TRUE,results_timely
NCT04124965,CRU trials_12Sep2023.xlsx,2023-08-22,2019-10-11,2023-07-27,Interventional,Phase 3,71,Completed,"A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis",2019-10-29T00:00:00Z,2021-09-01T00:00:00Z,2021-09-01T00:00:00Z,TRUE,Randomized,None (Open Label),INDUSTRY,TRUE,2019,2019,2021,TRUE,2023-11-11,2022-09-01,TRUE,694,FALSE,results_due_late
NCT04149457,CRU trials_12Sep2023.xlsx,2023-04-05,2019-10-28,NA,Interventional,Not Applicable,92,Recruiting,Improving Neurological Health in Aging Via Neuroplasticity-based Computerized Exercise,2021-07-16T00:00:00Z,2024-05-31T00:00:00Z,2024-05-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,FALSE,2019,2021,2024,TRUE,2023-11-11,2025-05-31,FALSE,NA,NA,results_not_due
NCT04155606,CRU trials_12Sep2023.xlsx,2023-06-30,2019-11-05,NA,Interventional,Not Applicable,2000,Recruiting,Comprehensive Aneurysm Management Trial,2020-01-15T00:00:00Z,2036-01-01T00:00:00Z,2035-01-01T00:00:00Z,FALSE,Randomized,None (Open Label),OTHER,TRUE,2019,2020,2036,TRUE,2023-11-11,2036-01-01,FALSE,NA,NA,results_not_due
NCT04164901,CRU trials_12Sep2023.xlsx,2023-07-07,2019-11-11,NA,Interventional,Phase 3,340,"Active, not recruiting",Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO),2020-01-05T00:00:00Z,2027-08-01T00:00:00Z,2024-10-01T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,TRUE,2019,2020,2027,TRUE,2023-11-11,2025-10-01,FALSE,NA,NA,results_not_due
NCT04165824,CRU trials_12Sep2023.xlsx,2023-05-12,2019-11-13,2022-08-05,Interventional,Phase 3,185,Completed,Safety Study of Oral Edaravone Administered in Subjects With ALS,2019-11-18T00:00:00Z,2021-10-07T00:00:00Z,2021-10-07T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE,2019,2019,2021,TRUE,2023-11-11,2022-10-07,TRUE,302,TRUE,results_timely
NCT04167527,CRU trials_12Sep2023.xlsx,2023-09-06,2019-11-15,NA,Interventional,Phase 2/Phase 3,200,Recruiting,Endovascular Therapy for Low NIHSS Ischemic Strokes,2020-09-05T00:00:00Z,2024-12-01T00:00:00Z,2024-12-01T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE,2019,2020,2024,TRUE,2023-11-11,2025-12-01,FALSE,NA,NA,results_not_due
NCT04192955,CRU trials_12Sep2023.xlsx,2023-05-04,2019-11-28,NA,Interventional,Phase 3,440,Recruiting,Evaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms,2020-07-14T00:00:00Z,2024-12-01T00:00:00Z,2024-09-01T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,TRUE,2019,2020,2024,TRUE,2023-11-11,2025-09-01,FALSE,NA,NA,results_not_due
NCT04225871,CRU trials_12Sep2023.xlsx,2023-08-03,2019-10-02,NA,Interventional,Phase 3,200,"Active, not recruiting",Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis,2019-12-23T00:00:00Z,2026-06-02T00:00:00Z,2026-06-02T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2019,2019,2026,TRUE,2023-11-11,2027-06-02,FALSE,NA,NA,results_not_due
NCT04241068,CRU trials_12Sep2023.xlsx,2023-04-13,2020-01-22,NA,Interventional,Phase 3,1696,"Active, not recruiting","A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",2020-03-02T00:00:00Z,2025-02-03T00:00:00Z,2023-10-20T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2020,2020,2025,TRUE,2023-11-11,2024-10-19,FALSE,NA,NA,results_not_due
NCT04248465,CRU trials_12Sep2023.xlsx,2022-12-15,2020-01-27,2022-09-22,Interventional,Phase 3,382,Terminated,An Efficacy and Safety Study of Ravulizumab in ALS Participants,2020-03-30T00:00:00Z,2021-10-17T00:00:00Z,2021-10-17T00:00:00Z,TRUE,Randomized,Quadruple,INDUSTRY,TRUE,2020,2020,2021,TRUE,2023-11-11,2022-10-17,TRUE,340,TRUE,results_timely
NCT04259255,CRU trials_12Sep2023.xlsx,2023-08-23,2020-01-27,NA,Observational,NA,300,"Active, not recruiting",Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS),2019-10-21T00:00:00Z,2024-03-01T00:00:00Z,2024-03-01T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2020,2019,2024,FALSE,2023-11-11,2025-03-01,FALSE,NA,NA,results_not_due
NCT04261478,CRU trials_12Sep2023.xlsx,2022-11-08,2020-02-03,NA,Interventional,Not Applicable,458,Recruiting,Endovascular Acute Stroke Intervention - Tandem OCclusion Trial,2020-08-31T00:00:00Z,2027-03-01T00:00:00Z,2026-06-01T00:00:00Z,FALSE,Randomized,Single,OTHER,FALSE,2020,2020,2027,TRUE,2023-11-11,2027-06-01,FALSE,NA,NA,results_not_due
NCT04288856,CRU trials_12Sep2023.xlsx,2023-04-13,2020-02-26,NA,Interventional,Phase 1,75,Terminated,"Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)",2020-04-28T00:00:00Z,2022-05-03T00:00:00Z,2022-05-03T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE,2020,2020,2022,TRUE,2023-11-11,2023-05-03,TRUE,NA,NA,results_due_missing
NCT04322149,CRU trials_12Sep2023.xlsx,2023-06-06,2020-03-20,2023-05-10,Interventional,Phase 2,54,Completed,Multiple Doses of AT-1501-A201 in Adults With ALS,2020-10-16T00:00:00Z,2022-03-24T00:00:00Z,2022-03-24T00:00:00Z,TRUE,NA,None (Open Label),INDUSTRY,TRUE,2020,2020,2022,TRUE,2023-11-11,2023-03-24,TRUE,412,FALSE,results_due_late
NCT04338022,CRU trials_12Sep2023.xlsx,2023-10-02,2020-04-06,NA,Interventional,Phase 3,1124,"Active, not recruiting",Study of Evobrutinib in Participants With RMS (evolutionRMS 1),2020-06-12T00:00:00Z,2026-06-26T00:00:00Z,2023-10-02T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2020,2020,2026,TRUE,2023-11-11,2024-10-01,FALSE,NA,NA,results_not_due
NCT04349514,CRU trials_12Sep2023.xlsx,2023-08-20,2020-04-01,NA,Observational,NA,300,Recruiting,A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals With Friedreich Ataxia (TRACK-FA),2021-02-10T00:00:00Z,2025-08-01T00:00:00Z,2025-08-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2020,2021,2025,TRUE,2023-11-11,2026-08-01,FALSE,NA,NA,results_not_due
NCT04411641,CRU trials_12Sep2023.xlsx,2023-02-09,2020-05-28,NA,Interventional,Phase 3,1131,"Active, not recruiting",Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),2020-09-24T00:00:00Z,2024-08-01T00:00:00Z,2024-08-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2020,2020,2024,TRUE,2023-11-11,2025-08-01,FALSE,NA,NA,results_not_due
NCT04458051,CRU trials_12Sep2023.xlsx,2023-08-15,2020-07-01,NA,Interventional,Phase 3,990,Recruiting,Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168),2020-08-13T00:00:00Z,2024-08-01T00:00:00Z,2024-08-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2020,2020,2024,TRUE,2023-11-11,2025-08-01,FALSE,NA,NA,results_not_due
NCT04462536,CRU trials_12Sep2023.xlsx,2023-09-08,2020-07-02,NA,Interventional,Phase 3,850,Completed,Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis,2020-12-06T00:00:00Z,2023-08-31T00:00:00Z,2023-08-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2020,2020,2023,TRUE,2023-11-11,2024-08-30,FALSE,NA,NA,results_not_due
NCT04477785,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-08-15,2020-07-15,NA,Observational,NA,4500,Recruiting,PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort,2020-07-01T00:00:00Z,2033-12-01T00:00:00Z,2033-12-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2020,2020,2033,TRUE,2023-11-11,2034-12-01,FALSE,NA,NA,results_not_due
NCT04494256,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-10-03,2020-07-30,NA,Interventional,Phase 1/Phase 2,99,"Active, not recruiting","A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation",2020-09-28T00:00:00Z,2026-07-15T00:00:00Z,2026-07-15T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2020,2020,2026,TRUE,2023-11-11,2027-07-15,FALSE,NA,NA,results_not_due
NCT04524273,CRU trials_12Sep2023.xlsx,2023-09-15,2020-08-10,NA,Interventional,Phase 3,270,Recruiting,Myasthenia Gravis Inebilizumab Trial,2020-08-30T00:00:00Z,2029-03-31T00:00:00Z,2024-10-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2020,2020,2029,TRUE,2023-11-11,2025-10-31,FALSE,NA,NA,results_not_due
NCT04539041,CRU trials_12Sep2023.xlsx,2023-10-11,2020-08-25,NA,Interventional,Phase 1,66,Recruiting,"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy",2021-02-16T00:00:00Z,2024-11-12T00:00:00Z,2024-11-12T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2020,2021,2024,TRUE,2023-11-11,2025-11-12,FALSE,NA,NA,results_not_due
NCT04544449,CRU trials_12Sep2023.xlsx,2023-09-11,2020-09-04,NA,Interventional,Phase 3,985,"Active, not recruiting",A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis,2020-10-26T00:00:00Z,2026-12-18T00:00:00Z,2026-01-16T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2020,2020,2026,TRUE,2023-11-11,2027-01-16,FALSE,NA,NA,results_not_due
NCT04548999,CRU trials_12Sep2023.xlsx,2023-11-01,2020-09-09,NA,Interventional,Phase 3,699,"Active, not recruiting","A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)",2020-12-03T00:00:00Z,2029-07-26T00:00:00Z,2025-11-12T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2020,2020,2029,TRUE,2023-11-11,2026-11-12,FALSE,NA,NA,results_not_due
NCT04569084,CRU trials_12Sep2023.xlsx,2023-10-26,2020-09-23,NA,Interventional,Phase 3,384,Terminated,Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS,2020-11-13T00:00:00Z,2023-09-29T00:00:00Z,2023-09-29T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2020,2020,2023,TRUE,2023-11-11,2024-09-28,FALSE,NA,NA,results_not_due
NCT04569435,CRU trials_12Sep2023.xlsx,2023-03-23,2020-09-23,NA,Interventional,Phase 2,24,Recruiting,Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS),2021-01-15T00:00:00Z,2024-01-01T00:00:00Z,2023-10-01T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2020,2021,2024,TRUE,2023-11-11,2024-09-30,FALSE,NA,NA,results_not_due
NCT04577404,CRU trials_12Sep2023.xlsx,2023-10-26,2020-09-30,NA,Interventional,Phase 3,124,Completed,Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS),2020-10-29T00:00:00Z,2023-08-08T00:00:00Z,2023-08-08T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2020,2020,2023,TRUE,2023-11-11,2024-08-07,FALSE,NA,NA,results_not_due
NCT04586023,CRU trials_12Sep2023.xlsx,2023-10-20,2020-10-08,NA,Interventional,Phase 3,736,Recruiting,Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS),2021-03-24T00:00:00Z,2025-11-27T00:00:00Z,2025-10-02T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2020,2021,2025,TRUE,2023-11-11,2026-10-02,FALSE,NA,NA,results_not_due
NCT04619420,CRU trials_12Sep2023.xlsx,2023-11-07,2020-11-05,NA,Interventional,Phase 2,523,"Active, not recruiting",A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease,2021-01-06T00:00:00Z,2025-11-05T00:00:00Z,2025-03-07T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2020,2021,2025,TRUE,2023-11-11,2026-03-07,FALSE,NA,NA,results_not_due
NCT04635891,CRU trials_12Sep2023.xlsx,2022-12-12,2020-10-29,NA,Observational,NA,450,Recruiting,Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD),2020-12-15T00:00:00Z,2024-01-01T00:00:00Z,2023-12-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2020,2020,2024,TRUE,2023-11-11,2024-11-30,FALSE,NA,NA,results_not_due
NCT04642443,CRU trials_12Sep2023.xlsx,2023-09-25,2020-11-19,NA,Interventional,Not Applicable,450,Recruiting,Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage,2020-12-23T00:00:00Z,2024-09-30T00:00:00Z,2024-06-30T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,FALSE,2020,2020,2024,TRUE,2023-11-11,2025-06-30,FALSE,NA,NA,results_not_due
NCT04650854,CRU trials_12Sep2023.xlsx,2023-11-02,2020-11-05,NA,Interventional,Phase 3,165,"Active, not recruiting",A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis,2021-02-03T00:00:00Z,2024-01-31T00:00:00Z,2024-01-31T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE,2020,2021,2024,TRUE,2023-11-11,2025-01-30,FALSE,NA,NA,results_not_due
NCT04686136,CRU trials_12Sep2023.xlsx,2023-03-22,2020-12-21,NA,Interventional,Phase 3,596,"Active, not recruiting",A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine,2021-02-19T00:00:00Z,2024-09-13T00:00:00Z,2024-09-13T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2020,2021,2024,TRUE,2023-11-11,2025-09-13,FALSE,NA,NA,results_not_due
NCT04747431,CRU trials_12Sep2023.xlsx,2023-11-02,2021-02-02,NA,Interventional,Phase 1/Phase 2,15,Recruiting,A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN),2021-09-14T00:00:00Z,2027-08-01T00:00:00Z,2024-08-01T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE,2021,2021,2027,TRUE,2023-11-11,2025-08-01,FALSE,NA,NA,results_not_due
NCT04762758,CRU trials_12Sep2023.xlsx,2023-04-04,2021-02-17,NA,Interventional,Phase 3,350,"Active, not recruiting",Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients,2021-03-30T00:00:00Z,2024-03-31T00:00:00Z,2023-10-31T00:00:00Z,FALSE,Randomized,Double,OTHER,TRUE,2021,2021,2024,TRUE,2023-11-11,2024-10-30,FALSE,NA,NA,results_not_due
NCT04768972,CRU trials_12Sep2023.xlsx,2023-09-14,2021-02-22,NA,Interventional,Phase 3,77,Recruiting,"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)",2021-06-14T00:00:00Z,2028-03-01T00:00:00Z,2026-06-01T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2028,TRUE,2023-11-11,2027-06-01,FALSE,NA,NA,results_not_due
NCT04777331,CRU trials_12Sep2023.xlsx,2023-11-01,2021-02-26,NA,Interventional,Phase 2,586,"Active, not recruiting",A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease,2021-05-05T00:00:00Z,2026-11-27T00:00:00Z,2024-09-20T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2026,TRUE,2023-11-11,2025-09-20,FALSE,NA,NA,results_not_due
NCT04783935,CRU trials_12Sep2023.xlsx,2023-09-07,2021-03-03,NA,Interventional,Phase 4,219,"Active, not recruiting",Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension),2021-03-10T00:00:00Z,2023-11-30T00:00:00Z,2023-11-30T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2021,2021,2023,TRUE,2023-11-11,2024-11-29,FALSE,NA,NA,results_not_due
NCT04840823,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-03-21,2021-03-29,NA,Interventional,Phase 1/Phase 2,36,"Active, not recruiting",Enoxacin for Amyotrophic Lateral Sclerosis (ALS),2021-03-26T00:00:00Z,2023-05-01T00:00:00Z,2023-05-01T00:00:00Z,FALSE,Randomized,Quadruple,OTHER,FALSE,2021,2021,2023,TRUE,2023-11-11,2024-04-30,FALSE,NA,NA,results_not_due
NCT04886518,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-08-23,2021-05-10,NA,Interventional,Phase 2,30,"Active, not recruiting",Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1,2021-06-28T00:00:00Z,2023-10-01T00:00:00Z,2023-09-01T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2023,TRUE,2023-11-11,2024-08-31,FALSE,NA,NA,results_not_due
NCT04893083,CRU trials_12Sep2023.xlsx,2023-10-26,2021-05-12,NA,Observational,NA,65,Terminated,A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease,2021-06-28T00:00:00Z,2023-09-22T00:00:00Z,2023-06-30T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2021,2021,2023,TRUE,2023-11-11,2024-06-29,FALSE,NA,NA,results_not_due
NCT04923984,CRU trials_12Sep2023.xlsx,2022-05-30,2021-06-07,NA,Interventional,Not Applicable,100,Recruiting,Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can),2021-05-01T00:00:00Z,2024-11-01T00:00:00Z,2024-03-01T00:00:00Z,FALSE,NA,None (Open Label),OTHER,FALSE,2021,2021,2024,FALSE,2023-11-11,2025-03-01,FALSE,NA,NA,results_not_due
NCT04926818,CRU trials_12Sep2023.xlsx,2023-10-09,2021-06-14,NA,Interventional,Phase 3,180,Recruiting,Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis,2021-10-05T00:00:00Z,2029-06-01T00:00:00Z,2026-08-04T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2021,2021,2029,TRUE,2023-11-11,2027-08-04,FALSE,NA,NA,results_not_due
NCT04931862,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-10-18,2021-06-11,NA,Interventional,Phase 1/Phase 2,35,Terminated,Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD),2021-06-28T00:00:00Z,2023-06-27T00:00:00Z,2023-06-27T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2023,TRUE,2023-11-11,2024-06-26,FALSE,NA,NA,results_not_due
NCT04935866,CRU trials_12Sep2023.xlsx,2022-08-16,2021-06-15,NA,Observational,NA,286,Recruiting,Optimal Brain Oxygenation in Neurologic Intensive Care Unit : The NeurO2 Study,2021-05-07T00:00:00Z,2025-07-01T00:00:00Z,2024-07-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2021,2021,2025,FALSE,2023-11-11,2025-07-01,FALSE,NA,NA,results_not_due
NCT04936542,CRU trials_12Sep2023.xlsx,2023-10-31,2021-06-09,NA,Interventional,Phase 4,564,Recruiting,A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.,2021-06-23T00:00:00Z,2024-06-28T00:00:00Z,2024-06-28T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2021,2021,2024,TRUE,2023-11-11,2025-06-28,FALSE,NA,NA,results_not_due
NCT04944784,CRU trials_12Sep2023.xlsx,2023-04-12,2021-06-16,NA,Interventional,Phase 3,486,Terminated,A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS),2021-08-16T00:00:00Z,2023-03-31T00:00:00Z,2023-03-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2021,2021,2023,TRUE,2023-11-11,2024-03-30,FALSE,NA,NA,results_not_due
NCT04948645,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-01-20,2021-06-23,NA,Interventional,Phase 1,31,"Active, not recruiting",A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis,2021-09-22T00:00:00Z,2025-12-01T00:00:00Z,2023-01-12T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2021,2021,2025,TRUE,2023-11-11,2024-01-12,FALSE,NA,NA,results_not_due
NCT04951622,CRU trials_12Sep2023.xlsx,2023-11-08,2021-06-30,NA,Interventional,Phase 3,198,Recruiting,A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis,2021-07-15T00:00:00Z,2026-04-17T00:00:00Z,2023-11-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2021,2021,2026,TRUE,2023-11-11,2024-10-31,FALSE,NA,NA,results_not_due
NCT04963270,CRU trials_12Sep2023.xlsx,2023-10-31,2021-07-07,NA,Interventional,Phase 3,185,Recruiting,"A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis",2021-10-19T00:00:00Z,2027-12-11T00:00:00Z,2024-01-31T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2027,TRUE,2023-11-11,2025-01-30,FALSE,NA,NA,results_not_due
NCT04980495,CRU trials_12Sep2023.xlsx,2023-10-09,2021-07-19,NA,Interventional,Phase 3,69,"Active, not recruiting",An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis,2021-12-16T00:00:00Z,2025-11-03T00:00:00Z,2023-08-24T00:00:00Z,FALSE,Randomized,None (Open Label),INDUSTRY,TRUE,2021,2021,2025,TRUE,2023-11-11,2024-08-23,FALSE,NA,NA,results_not_due
NCT05021991,CRU trials_12Sep2023.xlsx,2023-10-16,2021-08-20,NA,Interventional,Phase 2,131,"Active, not recruiting",A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor,2021-10-14T00:00:00Z,2023-12-01T00:00:00Z,2023-02-09T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2021,2021,2023,TRUE,2023-11-11,2024-02-09,FALSE,NA,NA,results_not_due
NCT05039099,TheNeuro_registered_clinical_trials.csv;CRU trials_12Sep2023.xlsx,2023-08-02,2021-09-01,NA,Interventional,Phase 2,63,Recruiting,"A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)",2021-09-02T00:00:00Z,2025-01-18T00:00:00Z,2024-06-28T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2025,TRUE,2023-11-11,2025-06-28,FALSE,NA,NA,results_not_due
NCT05054140,CRU trials_12Sep2023.xlsx,2023-01-31,2021-09-02,NA,Interventional,Phase 2,450,Recruiting,"Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis",2021-09-30T00:00:00Z,2024-07-28T00:00:00Z,2024-04-05T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2024,TRUE,2023-11-11,2025-04-05,FALSE,NA,NA,results_not_due
NCT05061953,TheNeuro_registered_clinical_trials.csv,2023-03-01,2021-09-21,NA,Observational,NA,168,Recruiting,Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,2021-10-18T00:00:00Z,2027-10-18T00:00:00Z,2027-10-18T00:00:00Z,FALSE,NA,NA,INDUSTRY,TRUE,2021,2021,2027,TRUE,2023-11-11,2028-10-17,FALSE,NA,NA,results_not_due
NCT05132569,CRU trials_12Sep2023.xlsx,2023-03-08,2021-11-12,NA,Interventional,Phase 3,6,Terminated,Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis,2021-12-03T00:00:00Z,2023-02-21T00:00:00Z,2023-02-21T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2021,2021,2023,TRUE,2023-11-11,2024-02-21,FALSE,NA,NA,results_not_due
NCT05151172,CRU trials_12Sep2023.xlsx,2023-09-27,2021-11-25,NA,Interventional,Not Applicable,530,Recruiting,EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial),2022-04-15T00:00:00Z,2026-08-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,Randomized,Single,OTHER,TRUE,2021,2022,2026,TRUE,2023-11-11,2026-12-31,FALSE,NA,NA,results_not_due
NCT05151471,CRU trials_12Sep2023.xlsx,2023-10-26,2021-11-28,NA,Interventional,Phase 3,202,Terminated,Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS,2022-01-11T00:00:00Z,2023-09-29T00:00:00Z,2023-09-29T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2021,2022,2023,TRUE,2023-11-11,2024-09-28,FALSE,NA,NA,results_not_due
NCT05204017,CRU trials_12Sep2023.xlsx,2023-05-10,2021-11-29,NA,Observational,NA,150,Recruiting,"Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS",2021-09-12T00:00:00Z,2025-07-01T00:00:00Z,2024-01-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2021,2021,2025,FALSE,2023-11-11,2024-12-31,FALSE,NA,NA,results_not_due
NCT05216250,CRU trials_12Sep2023.xlsx,2023-10-18,2021-10-01,NA,Interventional,Phase 2,174,Recruiting,Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor,2022-04-12T00:00:00Z,2025-02-27T00:00:00Z,2024-11-15T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2021,2022,2025,TRUE,2023-11-11,2025-11-15,FALSE,NA,NA,results_not_due
NCT05231785,CRU trials_12Sep2023.xlsx,2023-10-20,2022-01-30,NA,Interventional,Phase 1,60,Recruiting,A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD,2022-02-04T00:00:00Z,2025-07-01T00:00:00Z,2025-07-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2022,2022,2025,TRUE,2023-11-11,2026-07-01,FALSE,NA,NA,results_not_due
NCT05237284,CRU trials_12Sep2023.xlsx,2023-09-22,2022-02-02,NA,Interventional,Phase 2,305,"Active, not recruiting",Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS),2022-04-13T00:00:00Z,2025-07-24T00:00:00Z,2024-01-16T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2022,2022,2025,TRUE,2023-11-11,2025-01-15,FALSE,NA,NA,results_not_due
NCT05269004,CRU trials_12Sep2023.xlsx,2023-10-06,2022-02-11,NA,Interventional,Phase 3,1300,"Active, not recruiting",A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis,2022-05-03T00:00:00Z,2025-12-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2022,2022,2025,TRUE,2023-11-11,2026-12-31,FALSE,NA,NA,results_not_due
NCT05269667,CRU trials_12Sep2023.xlsx,2023-11-06,2022-02-15,NA,Interventional,Phase 4,4,Terminated,A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention,2022-08-02T00:00:00Z,2023-10-26T00:00:00Z,2023-10-26T00:00:00Z,FALSE,Non-Randomized,None (Open Label),INDUSTRY,TRUE,2022,2022,2023,TRUE,2023-11-11,2024-10-25,FALSE,NA,NA,results_not_due
NCT05271409,CRU trials_12Sep2023.xlsx,2023-10-25,2022-02-28,NA,Interventional,Phase 3,152,Recruiting,"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease",2022-08-30T00:00:00Z,2028-12-31T00:00:00Z,2026-04-30T00:00:00Z,FALSE,Randomized,Double,INDUSTRY,TRUE,2022,2022,2028,TRUE,2023-11-11,2027-04-30,FALSE,NA,NA,results_not_due
NCT05348785,CRU trials_12Sep2023.xlsx,2023-10-11,2022-04-04,NA,Interventional,Phase 2,640,Recruiting,A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80,2022-04-19T00:00:00Z,2025-08-28T00:00:00Z,2025-08-15T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2022,2022,2025,TRUE,2023-11-11,2026-08-15,FALSE,NA,NA,results_not_due
NCT05349721,CRU trials_12Sep2023.xlsx,2023-10-11,2022-04-21,NA,Interventional,Phase 2,258,Recruiting,Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS,2022-05-15T00:00:00Z,2025-02-28T00:00:00Z,2024-07-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2022,2022,2025,TRUE,2023-11-11,2025-07-31,FALSE,NA,NA,results_not_due
NCT05397470,CRU trials_12Sep2023.xlsx,2023-09-27,2022-05-04,NA,Interventional,Phase 3,260,"Active, not recruiting",Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH),2022-06-16T00:00:00Z,2026-01-01T00:00:00Z,2024-10-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2022,2022,2026,TRUE,2023-11-11,2025-10-01,FALSE,NA,NA,results_not_due
NCT05399888,CRU trials_12Sep2023.xlsx,2023-10-25,2022-05-27,NA,Interventional,Phase 2,735,Recruiting,"A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into the Cerebrospinal Fluid of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age",2022-08-24T00:00:00Z,2026-12-14T00:00:00Z,2026-12-14T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2022,2022,2026,TRUE,2023-11-11,2027-12-14,FALSE,NA,NA,results_not_due
NCT05403541,CRU trials_12Sep2023.xlsx,2023-10-11,2022-05-26,NA,Interventional,Phase 3,210,Recruiting,Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis,2022-06-27T00:00:00Z,2025-04-01T00:00:00Z,2024-04-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2022,2022,2025,TRUE,2023-11-11,2025-04-01,FALSE,NA,NA,results_not_due
NCT05407324,CRU trials_12Sep2023.xlsx,2023-10-25,2022-06-02,NA,Interventional,Phase 2,198,Recruiting,Dazucorilant in Patients With Amyotrophic Lateral Sclerosis,2022-11-15T00:00:00Z,2024-11-01T00:00:00Z,2024-05-01T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2022,2022,2024,TRUE,2023-11-11,2025-05-01,FALSE,NA,NA,results_not_due
NCT05442775,CRU trials_12Sep2023.xlsx,2023-04-12,2022-06-16,NA,Interventional,Phase 3,72,Terminated,"A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)",2022-07-25T00:00:00Z,2023-03-31T00:00:00Z,2023-03-31T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2022,2022,2023,TRUE,2023-11-11,2024-03-30,FALSE,NA,NA,results_not_due
NCT05602727,CRU trials_12Sep2023.xlsx,2023-10-20,2022-10-27,NA,Interventional,Phase 2,99,Terminated,Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008),2022-12-02T00:00:00Z,2023-09-27T00:00:00Z,2023-09-27T00:00:00Z,FALSE,Randomized,Triple,INDUSTRY,TRUE,2022,2022,2023,TRUE,2023-11-11,2024-09-26,FALSE,NA,NA,results_not_due
NCT05633459,CRU trials_12Sep2023.xlsx,2023-10-19,2022-11-21,NA,Interventional,Phase 1,64,Recruiting,A Study Evaluating the Safety and Tolerability of QRL-201 in ALS,2022-12-16T00:00:00Z,2025-05-06T00:00:00Z,2025-05-06T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2022,2022,2025,TRUE,2023-11-11,2026-05-06,FALSE,NA,NA,results_not_due
NCT05686070,CRU trials_12Sep2023.xlsx,2023-11-08,2023-01-06,NA,Interventional,Phase 3,9300,Recruiting,A Study to Test Asundexian to Prevent a Clot-related Stroke in Participants After an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack),2023-01-26T00:00:00Z,2025-10-10T00:00:00Z,2025-10-10T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2023,2023,2025,TRUE,2023-11-11,2026-10-10,FALSE,NA,NA,results_not_due
NCT05686551,CRU trials_12Sep2023.xlsx,2023-11-06,2022-12-16,NA,Interventional,Phase 2,300,Recruiting,"GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.",2023-02-03T00:00:00Z,2027-01-04T00:00:00Z,2025-01-03T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2022,2023,2027,TRUE,2023-11-11,2026-01-03,FALSE,NA,NA,results_not_due
NCT05704361,CRU trials_12Sep2023.xlsx,2023-10-11,2023-01-04,NA,Interventional,Phase 1,63,Recruiting,"A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis.",2021-08-11T00:00:00Z,2025-01-31T00:00:00Z,2025-01-31T00:00:00Z,FALSE,NA,None (Open Label),INDUSTRY,TRUE,2023,2021,2025,FALSE,2023-11-11,2026-01-31,FALSE,NA,NA,results_not_due
NCT05779813,CRU trials_12Sep2023.xlsx,2023-03-23,2023-02-27,NA,Observational,NA,200,Recruiting,Genetic Frontotemporal Dementia Initiative for Neurodevelopment,2023-03-01T00:00:00Z,2035-03-01T00:00:00Z,2033-03-01T00:00:00Z,FALSE,NA,NA,OTHER,FALSE,2023,2023,2035,TRUE,2023-11-11,2034-03-01,FALSE,NA,NA,results_not_due
NCT05819359,CRU trials_12Sep2023.xlsx,2023-10-26,2023-04-06,NA,Interventional,Phase 2,237,Recruiting,"Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD",2023-03-31T00:00:00Z,2026-03-31T00:00:00Z,2025-12-31T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2023,2023,2026,FALSE,2023-11-11,2026-12-31,FALSE,NA,NA,results_not_due
NCT05826457,CRU trials_12Sep2023.xlsx,2023-04-20,2023-02-08,NA,Observational,NA,500,Recruiting,North American Prodromal Synucleinopathy Consortium Stage 2,2022-08-12T00:00:00Z,2025-05-01T00:00:00Z,2025-05-01T00:00:00Z,FALSE,NA,NA,OTHER,TRUE,2023,2022,2025,FALSE,2023-11-11,2026-05-01,FALSE,NA,NA,results_not_due
NCT05908695,CRU trials_12Sep2023.xlsx,2023-11-08,2023-05-31,NA,Interventional,Phase 4,1312,Recruiting,An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease,2023-08-31T00:00:00Z,2029-12-01T00:00:00Z,2029-06-01T00:00:00Z,FALSE,Randomized,Quadruple,INDUSTRY,TRUE,2023,2023,2029,TRUE,2023-11-11,2030-06-01,FALSE,NA,NA,results_not_due
NCT06038643,CRU trials_12Sep2023.xlsx,2023-10-29,2022-04-25,NA,Interventional,Not Applicable,80,Recruiting,Intergenerational Behavioral Intervention to Enhance Physical Activity in Older Adults at Risk for Alzheimer's Disease,2023-10-24T00:00:00Z,2024-05-30T00:00:00Z,2024-02-20T00:00:00Z,FALSE,Randomized,Double,OTHER,FALSE,2022,2023,2024,TRUE,2023-11-11,2025-02-19,FALSE,NA,NA,results_not_due
